Gout Treatment Advances: Shanton Pharma’s SAP-001 and Its Potential Impact

Gout Treatment Advances: Shanton Pharma’s SAP-001 and Its Potential Impact Shanton Pharma has recently announced the full enrollment of its Phase IIb clinical trial for SAP-001, a promising new treatment for refractory and tophaceous gout. This milestone marks a significant step forward in the development of therapies aimed at addressing the unmet medical needs of […]